Skip to main content
Year archive

ACTINOGEN MEDICAL LIMITED — 2016 filings

All 39 regulatory filings released by ACTINOGEN MEDICAL LIMITED (ACW) in 2016, sourced directly from the official regulator.

39 Filings
2016 Period
2016 filings (39)
Filing Released Lang
Trading Halt 3 pages 208.8KB
Regulatory Filings
2016-12-29 English
Significant Advance in Development of Alzheimer's Drug 2 pages 163.7KB
Regulatory Filings
2016-12-18 English
Xanamem Research Presented at CTAD 2 pages 137.6KB
Regulatory Filings
2016-12-05 English
Chairman's AGM Address 3 pages 147.9KB
AGM Information
2016-11-29 English
CEO's Presentation to AGM 17 pages 1.8MB
AGM Information
2016-11-29 English
Results of Annual General Meeting 2 pages 120.8KB
Declaration of Voting Results & Voting Rights Announcements
2016-11-29 English
Resignation of Director 2 pages 109.0KB
Board/Management Information
2016-11-29 English
Appendix 3Z 2 pages 175.7KB
Director's Dealing
2016-11-29 English
Appendix 4C - quarterly 5 pages 50.9KB
Interim / Quarterly Report
2016-10-25 English
Notice of Annual General Meeting/Proxy Form 19 pages 427.8KB
AGM Information
2016-10-23 English
Annual Report to Shareholders 79 pages 2.4MB
Regulatory Filings
2016-10-23 English
Ceasing to be a substantial holder 2 pages 1.2MB
Regulatory Filings
2016-10-13 English
Ceasing to be a substantial holder 1 page 371.0KB
Regulatory Filings
2016-10-05 English
Changes to the Actinogen Medical Board 2 pages 113.1KB
Board/Management Information
2016-10-04 English
FDA Feedback on Xanamem Alzheimer's Trail 1 page 11
Regulatory Filings
2016-09-28 English
R&D Tax Rebate 1 page 109.7KB
Regulatory Filings
2016-09-04 English
Investor Update-August 2016 8 pages 820.4KB
Investor Presentation
2016-08-31 English
Appendix 4E & Financial Statements 81 pages 2.7MB
Regulatory Filings
2016-08-30 English
Appendix 4G 8 pages 93.3KB
Governance Information
2016-08-30 English
Ceasing to be a substantial holder 3 pages 1.0MB
Regulatory Filings
2016-08-23 English
Less Than Marketable Parcel Sale 5 pages 156.1KB
Capital/Financing Update
2016-08-16 English
Landmark Research on Excess Cortisol & Alzheimer's Disease 3 pages 210.4KB
Regulatory Filings
2016-07-27 English
US Patent Granted-Further Extends Xanamem Protection 2 pages 125.7KB
Regulatory Filings
2016-07-19 English
Appendix 4C - quarterly 5 pages 86.5KB
Interim / Quarterly Report
2016-07-14 English
US Roadshow Investor Presentation 31 pages 2.6MB
Investor Presentation
2016-07-14 English
Issue of Employee Options 13 pages 243.4KB
Capital/Financing Update
2016-07-07 English
Xanamem & AIBL to showcase Cortisol Hypothesis in Alzheimers 2 pages 154.1KB
Regulatory Filings
2016-06-28 English
US FDA Feedback Enhances Alzheimers Study 2 pages 115.9KB
Regulatory Filings
2016-06-07 English
Change of Share Register Notification 2 pages 103.5KB
Regulatory Filings
2016-05-19 English
Appendix 3B 12 pages 152.1KB
Capital/Financing Update
2016-05-05 English
Section 708A Notice 1 page 93.4KB
Share Issue/Capital Change
2016-05-05 English
BioEquity & Ausbiotech Asia Investor Presentation May 2016 31 pages 3.6MB
Investor Presentation
2016-05-02 English
Appendix 4C - quarterly 5 pages 86.3KB
Interim / Quarterly Report
2016-04-14 English
Launch of XanADu Phase II Clinical Trial 3 pages 147.1KB
Regulatory Filings
2016-03-21 English
Xanamem Cortisol Hypothesis-Investor Presentation 27 pages 2.2MB
Investor Presentation
2016-03-09 English
Appendix 4D & Half Year Report 25 pages 630.0KB
Interim / Quarterly Report
2016-02-18 English
R&D Rebate 1 page 100.0KB
Regulatory Filings
2016-02-08 English
Appendix 4C - quarterly 5 pages 86.2KB
Interim / Quarterly Report
2016-01-26 English
Appendix 3Y-Dr Bill Ketelbey 2 pages 25.7KB
Director's Dealing
2016-01-03 English